SAN DIEGO, United States, January 22, 2025 -- SeekIn Inc, aleader in blood-based cancer early detection and monitoring technology, published its innovative two-step multi-cancer screening strategy that is designed to significantly alleviate the financial burden of population-wide screening,
offering more affordable Multi-Cancer Early Detection (MCED) tests.
A groundbreaking study published in thejournal Cancer Research Communications introduces a novel two-step approach for MCED that promises to significantly enhance cancer screening efficiency while reducing costs and false positives. The research, led by Dr. Mao Mao and a team of experts from SeekIn Inc, addresses critical challenges in population-wide cancer screening. The study focuses on the implementation of OncoSeek, an initial screening test utilizing seven protein tumor markers and
artificial intelligence, followed by SeekInCare, a secondary genomic test for individuals who test positive in the first round. This innovative method not only minimizes the false positives but also alleviates the financial burden on healthcare systems.
Key Findings:
- Reduction in False Positives: The two-step approach reduces false positives from 441,450 to just 34,335 when applied to a simulated population of five million adults aged 50 and older. This translates to a decrease in the false positive rate from 9.0% to 0.7%.
- Cost-effectiveness: The total cost of implementing this two-step MCED strategy is approximately $713.6 million, or $143 per individual screened. In comparison, alternative methods like SeekInCare and Galleri would cost $3,750 million and $4,745 million respectively.
- Comparable Performance: While the two-step MCED identified 21,280 cancer cases, its positive predictive value (PPV) of 38.3% is comparable to that of SeekInCare and Galleri, which stand at 27.7% and 38.3%, respectively.
Significance of the Research
This study highlights a critical advancementin cancer screening methodologies that can potentially transform public health strategies. By minimizing false positives and reducing costs, the two-step MCED approach could facilitate broader access to cancer screening programs, ultimately leading to earlier detection and improved patient outcomes. The publication can be found at https://aacrjournals.org/cancerrescommun/article/doi/10.1158/2767-9764.CRC-24-0508/750782/A-cost-effective-two-step-approach-for-multi
About OncoSeek®
OncoSeek® has been developed as a multi-cancerdetection test that uses artificial intelligence to distinguish between cancer patients and non-cancer individuals by calculating the probability of cancer (POC) index based on the plasma levels of seven PTMs (i.e. AFP, CA125, CA15-3, CA19-9, CA72-4, CEA, and CYFRA21-1), gender and age of the subjects. OncoSeek® is anon-invasive, efficient, and cost-effective approach for multi-cancer early detection. OncoSeek® received CE-IVDMark in September 2022.
About SeekInCare®
With the mission to detect cancer while it is still curable, SeekInCare®has been developed as a pan-cancer detection test that takes a panoramic view
of blood cell-free cancer signatures and a multi-omics approach incorporating genomic and epigenetic alterations in conjunction with clinically validated
protein biomarkers. Equipped with proprietary AI- and big data-driven CRS algorithm, SeekInCare exhibits superior effectiveness to detect dozens of cancer types at high specificity. SeekInCare is intended for use in individuals with elevated risks of cancer such as smoking, chronic hepatitis, aging, etc., in conjunction with the approved conventional single-cancer type screening tests. SeekInCare received CE-IVD Mark in November 2021.
About SeekIn
SeekIn Inc is a biotech company founded in early 2018in Shenzhen, China, focusing on blood-based pan-cancer early detection utilizing next-generation sequencing and artificial intelligence. Since its creation, SeekIn has been committed to providing cutting-edge and cost-effective solutions for cancer early detection, postoperative recurrence monitoring, and treatment response evaluation. SeekIn has also developed novel molecular tests for leukemia patients and its cancer early detection technology has also successfully been applied to canines. With its proprietary technical advances, SeekIn has launched a number of research and clinical studies in collaboration with top-tier hospitals in China. SeekIn envisions that, by leading a new norm for cancer early detection, the clinical outcomes of mid-/late-stage cancer patients can be reversed, and the cancer mortality rate can be reduced by 15%. For more information about SeekIn's cutting-edge technologies and products, visit www.seekincancer.com.